These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 16106015)

  • 1. Gefitinib versus cetuximab in lung cancer: round one.
    Minna JD; Peyton MJ; Gazdar AF
    J Natl Cancer Inst; 2005 Aug; 97(16):1168-9. PubMed ID: 16106015
    [No Abstract]   [Full Text] [Related]  

  • 2. Epidermal growth factor inhibition in solid tumours.
    Ganti AK; Potti A
    Expert Opin Biol Ther; 2005 Sep; 5(9):1165-74. PubMed ID: 16120047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.
    Mukohara T; Engelman JA; Hanna NH; Yeap BY; Kobayashi S; Lindeman N; Halmos B; Pearlberg J; Tsuchihashi Z; Cantley LC; Tenen DG; Johnson BE; Jänne PA
    J Natl Cancer Inst; 2005 Aug; 97(16):1185-94. PubMed ID: 16106023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study.
    Ramalingam S; Forster J; Naret C; Evans T; Sulecki M; Lu H; Teegarden P; Weber MR; Belani CP
    J Thorac Oncol; 2008 Mar; 3(3):258-64. PubMed ID: 18317068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical treatment of non-small-cell lung cancer.
    Buter J; Giaccone G
    Ann Oncol; 2005; 16 Suppl 2():ii229-32. PubMed ID: 15958463
    [No Abstract]   [Full Text] [Related]  

  • 6. Research unveils the 'who' and 'why' of gefitinib.
    Vastag B
    J Natl Cancer Inst; 2004 Sep; 96(18):1352-4. PubMed ID: 15367564
    [No Abstract]   [Full Text] [Related]  

  • 7. [Targeting epidermal growth factor receptor in non-small cell lung cancer: current advances and perspectives].
    Italiano A; Besse B; Planchard D; Soria JC
    Bull Cancer; 2007; 94(7 Suppl):F177-88. PubMed ID: 17964994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of cetuximab after failure of gefitinib in patients with advanced non-small-cell lung cancer.
    Wu JY; Yang CH; Hsu YC; Yu CJ; Chang SH; Shih JY; Yang PC
    Clin Lung Cancer; 2010 Jul; 11(4):257-63. PubMed ID: 20630828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR inhibition in NSCLC: the emerging role of cetuximab.
    Herbst RS
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S41-51. PubMed ID: 19780245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the epidermal growth factor receptor a new strategy in cancer treatment.
    Gianni L; Grasselli G
    Suppl Tumori; 2002; 1(4):S60-1. PubMed ID: 12415824
    [No Abstract]   [Full Text] [Related]  

  • 12. Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor.
    Harichand-Herdt S; Ramalingam SS
    Semin Thorac Cardiovasc Surg; 2008; 20(3):217-23. PubMed ID: 19038731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer.
    Bunn PA; Franklin W
    Semin Oncol; 2002 Oct; 29(5 Suppl 14):38-44. PubMed ID: 12422312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Inhibitors of the EGFR pathway in non small cell lung cancer: what's new in 2007?].
    Grenier J; Soria JC
    Bull Cancer; 2007 Jan; 94(1):53-61. PubMed ID: 17237005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [From ASCO and WCLC 2005 to the clinical practice: targeted therapies].
    Pérol M
    Rev Pneumol Clin; 2006 Feb; 62 Spec no 1():1S30-4. PubMed ID: 16719154
    [No Abstract]   [Full Text] [Related]  

  • 16. [EGFR inhibitors in non-small cell lung cancer: more than yesterday (but less than tomorrow)].
    Cortot AB
    Rev Pneumol Clin; 2010 Dec; 66(6):367-74. PubMed ID: 21167447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers.
    Yonesaka K; Zejnullahu K; Lindeman N; Homes AJ; Jackman DM; Zhao F; Rogers AM; Johnson BE; Jänne PA
    Clin Cancer Res; 2008 Nov; 14(21):6963-73. PubMed ID: 18980991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR pathway in advanced non-small cell lung cancer.
    Merlo V; Longo M; Novello S; Scagliotti GV
    Front Biosci (Schol Ed); 2011 Jan; 3(2):501-17. PubMed ID: 21196393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer.
    Comis RL
    Oncologist; 2005 Aug; 10(7):467-70. PubMed ID: 16079313
    [No Abstract]   [Full Text] [Related]  

  • 20. Targeting the epidermal growth factor receptor in non-small-cell lung cancer: who, which, when, and how?
    Juergens R; Brahmer J
    Curr Oncol Rep; 2007 Jul; 9(4):255-64. PubMed ID: 17588349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.